PSUSA/00000761/202408
Submitted by Anonymous (not verified) on 6 May 2025 - 16:28
PSUSA/00000761/202408
PSUSA/00010464/202407
Submitted by Anonymous (not verified) on 6 May 2025 - 16:25
PSUSA/00010464/202407
Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 44, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 16:20
Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 44, Status: Authorised
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 16:12
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 16:05
Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 6, Status: Authorised
List of medicines currently in PRIME scheme
Submitted by Anonymous (not verified) on 6 May 2025 - 16:00
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 15:53
Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 48, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 15:45
Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 48, Status: Authorised
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 15:45
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 6 May 2025 - 15:40
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 19, Status: Authorised